Avalo Therapeutics (AVTX) | Finance information

Compare Avalo Therapeutics

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Avalo Therapeutics Inc	-0.4	0%	-432%	10.8	-
Market Avg	54.3	1.27%	32%	-	1.3
Healthcare Avg	39.1	1.36%	17%	7.2	1.3

$35.00

Target Price by Analysts

223.5% upsideAvalo Therapeutics Target Price Details

$-0.02

Current Fair Value

100.2% downside

Overvalued by 100.2% based on the discounted cash flow analysis.

Share Statistics

Market cap	$11.22 Million
Enterprise Value	$3.81 Million
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$-0.11
Beta	0.0
Outstanding Shares	1,034,130
Avg 30 Day Volume	86,970

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	-0.36
PEG	2.12
Price to Sales	10.82
Price to Book Ratio	1.55
Enterprise Value to Revenue	1.98
Enterprise Value to EBIT	-0.16
Enterprise Value to Net Income	-1
Total Debt to Enterprise	0
Debt to Equity	0

Revenue Sources

No data

ESG Score

No data

About Avalo Therapeutics Inc

31 employees

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...